C21 Investments (CXXI) AI Stock Analysis

• Market Cap: C$58.89M
• Dividend Yield: N/A
• Average Volume (3M): 63.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: 21.71%
• EPS Growth: 18.75%
• Country: CA
• Employees: 114
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 117,772,810
• 10 Day Avg. Volume: 17,290
• 30 Day Avg. Volume: 63,065
• PEG Ratio: -1.08
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.66
• P/FCF Ratio: -7.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$0.50 ▼(-12.28% Downside)

C21 Investments' overall stock score is primarily influenced by its mixed financial performance and valuation challenges. While there are some positive technical indicators, the negative P/E ratio and lack of dividend yield weigh heavily on the score.

C21 Investments Business Overview & Revenue Model

Company Description

C21 Investments (CXXI) is a diversified investment company focused on the cannabis sector, particularly in the cultivation, processing, and retail of cannabis products. The company operates in various states where cannabis is legal, providing a wide range of products that include dried flower, edibles, and concentrates. C21 Investments aims to leverage its expertise in the cannabis industry to capitalize on growth opportunities and enhance shareholder value.

How the Company Makes Money

C21 Investments generates revenue primarily through the sale of cannabis products from its dispensaries and cultivation facilities. The company operates retail outlets that sell a variety of cannabis goods, which represent a significant portion of its revenue. Additionally, C21 Investments earns money from wholesale distribution to other dispensaries and businesses in the cannabis supply chain. Key revenue streams include direct sales from retail locations, wholesale transactions, and potentially licensing agreements that allow other businesses to sell C21 products. The company may also benefit from strategic partnerships with suppliers, distributors, and other players in the cannabis industry, which can enhance its market reach and operational efficiency.

C21 Investments Financial Statement Overview

Summary

C21 Investments shows a mixed financial performance with positive revenue growth but negative net profit margin and cash flow challenges. The balance sheet is stable, but profitability issues persist.

Income Statement

C21 Investments shows a mixed performance in its income statement. The company has a positive revenue growth rate of 6.5% TTM, indicating some recovery. However, the net profit margin is negative at -10.34% TTM, reflecting ongoing profitability challenges. The gross profit margin is moderate at 42.13% TTM, but the EBIT and EBITDA margins are relatively low, suggesting limited operational efficiency.

Balance Sheet

The balance sheet of C21 Investments presents a stable debt-to-equity ratio of 0.46 TTM, indicating manageable leverage. However, the return on equity is negative at -11.32% TTM, highlighting profitability issues. The equity ratio is not explicitly calculated, but the company's equity position appears stable relative to its assets.

Cash Flow

C21 Investments faces challenges in cash flow management. The free cash flow growth rate is significantly negative, and the operating cash flow to net income ratio is low at 0.14 TTM, indicating cash flow constraints. The free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	32.08M	30.12M	28.29M	32.98M	28.89M	37.70M
Gross Profit	13.51M	12.56M	11.15M	18.81M	13.40M	13.32M
EBITDA	4.57M	2.90M	2.63M	20.72M	6.98M	-19.56M
Net Income	-3.32M	-3.97M	-3.31M	9.96M	293.21K	-32.56M
Balance Sheet
Total Assets	56.40M	57.00M	54.53M	61.85M	58.31M	61.45M
Cash, Cash Equivalents and Short-Term Investments	2.66M	2.63M	2.41M	3.07M	1.89M	3.08M
Total Debt	12.88M	13.15M	10.72M	18.67M	12.14M	36.07M
Total Liabilities	28.50M	28.32M	23.48M	26.87M	24.00M	47.87M
Stockholders Equity	27.90M	28.68M	31.05M	34.98M	34.32M	13.58M
Cash Flow
Free Cash Flow	844.24K	-2.63M	5.46M	4.27M	5.46M	5.00M
Operating Cash Flow	1.12M	1.19M	5.90M	6.84M	5.90M	5.51M
Investing Cash Flow	423.26K	-3.12M	-390.93K	-1.39M	-390.93K	-4.54M
Financing Cash Flow	-2.02M	1.27M	-6.68M	-7.84M	-6.68M	-7.10M

C21 Investments Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.57
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CXXI, the sentiment is Neutral. The current price of 0.57 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.51, and above the 200-day MA of 0.32, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 18.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:CXXI.

C21 Investments Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EPIC	66 Neutral	C$26.49M	15.20	6.23%	―	34.71%	―
VEXT	61 Neutral	C$65.61M	―	-20.91%	―	36.50%	-306.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ROMJ	51 Neutral	$33.25M	183.33	0.61%	―	34.19%	―
CXXI	49 Neutral	C$58.89M	―	-10.63%	―	21.71%	18.75%
AVCN	45 Neutral	$28.86M	-18.28	-109.32%	―	2.00%	80.83%
GWAY	44 Neutral	C$20.50M	―	-15.75%	―	26.75%	61.79%

C21 Investments Corporate Events

C21 Investments Issues New Shares to Maintain Foreign Private Issuer Status

On September 8, 2025, C21 Investments Inc. announced the issuance of 100,000,000 Subordinate Voting Shares at a nominal price to maintain its status as a ‘foreign private issuer’ under U.S. securities law. This move is intended to reduce compliance costs and does not result in a change of control for the company.

The most recent analyst rating on (TSE:CXXI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on C21 Investments stock, see the TSE:CXXI Stock Forecast page.

C21 Investments Completes Strategic Share Structure Adjustment

C21 Investments Inc. has completed a transaction to create and issue a new class of subordinate voting shares, designed to maintain its status as a foreign private issuer in the United States and reduce compliance costs. This move is strategic for the company as it ensures no impact on the economic or voting rights of existing common shareholders, while providing flexibility in share structure and maintaining regulatory compliance.

The most recent analyst rating on (TSE:CXXI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on C21 Investments stock, see the TSE:CXXI Stock Forecast page.

C21 Investments Settles Eco Firma Farms Litigation, Stabilizes Financial Position

C21 Investments Inc. has reached a settlement agreement regarding litigation involving its subsidiary Eco Firma Farms, resolving disputes with Proudest Monkey Holdings and its owners. The settlement, which includes a cash payment of $2.4 million and issuance of company shares, will dismiss all claims and offset certain financial liabilities, potentially stabilizing C21’s financial position and allowing it to focus on its core business operations.

The most recent analyst rating on (TSE:CXXI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on C21 Investments stock, see the TSE:CXXI Stock Forecast page.

C21 Investments Announces September 2025 Shareholder Meeting

C21 Investments Inc. has announced its upcoming Annual General Meeting of shareholders, scheduled for September 23, 2025, in Vancouver, British Columbia. The meeting will address several key issues, including the presentation of audited financial statements for the year ending March 31, 2025, the election of four directors, and the appointment of an auditor for the upcoming year. Shareholders of record as of July 30, 2025, are eligible to vote, and those unable to attend in person are encouraged to submit their proxies by September 19, 2025. This meeting is crucial for stakeholders as it will shape the company’s governance and financial oversight for the coming year.

The most recent analyst rating on (TSE:CXXI) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on C21 Investments stock, see the TSE:CXXI Stock Forecast page.

C21 Investments Announces Amendment for September 2025 Meeting

C21 Investments Inc. has announced an amendment regarding its upcoming Annual and Special Meeting of Security Holders, scheduled for September 23, 2025, in Vancouver, BC. The meeting will address matters pertinent to the company’s stakeholders, with record dates for notice and voting set for July 30, 2025. This announcement is significant as it outlines the procedural details for the meeting, which could impact shareholder decisions and the company’s strategic direction.

C21 Investments Announces Amended Notice for September AGM

C21 Investments Inc. announced an amended notice for its upcoming Annual General Meeting of Security Holders, scheduled for September 23, 2025, in Vancouver, BC. The record date for notice and voting was set for July 30, 2025. This announcement is significant for stakeholders as it outlines the procedural details of the meeting, which is crucial for shareholder engagement and governance.